AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

OSUR · NASDAQ · Medical - Instruments & Supplies

OraSure Technologies

Makes OraQuick tests and sample-management devices for decentralized diagnostics.

$3.60

After-hours close0.00 (0.00%)

At close$3.60(−2.44%)

Something off on this page? Send us feedback.

Profile

OraSure Technologies, Inc.OSURHealth Care

Sells rapid diagnostics for HIV and other conditions, plus sample-collection and stabilization devices for genomics and microbiome workflows. A single reportable segment houses products such as OraQuick, InteliSwab, Oragene, ORAcollect, OMNIgene, SickleSCAN, and the Sherlock molecular test pipeline.

Develops, manufactures, markets, sells, and distributes rapid diagnostics and sample-management solutions from Bethlehem, Pennsylvania. Product families include OraQuick HIV tests, other infectious-disease diagnostics for HCV, syphilis and Ebola, InteliSwab COVID-19 tests, and Genomics collection systems such as Oragene, ORAcollect and OMNIgene.

Uses oral-fluid, saliva, urine, blood and stool collection formats to support point-of-need testing and lab workflows. DNA Genotek anchors sample management; Sherlock adds a rapid molecular self-test platform; SickleSCAN adds point-of-care sickle-cell testing sold outside the United States.

Operates as one reportable segment, so the business is managed under a single reporting hierarchy rather than by product silo. COVID-19 test demand has normalized, and the Sherlock CT/NG self-test pipeline remains subject to regulatory approvals.

Company facts

CEOCarrie Eglinton Manner

ListedNov 17, 1986

ExchangeNASDAQ

HeadquartersBethlehem, PA

CountryUnited States

Employees500

CIK0001116463

ISINUS68554V1089

Key statistics

Market cap$247.9M

EPS (ttm)−$0.6900

P/E (ttm)−5.22

ROE-14.7%

P/B0.7817

P/S2.20

Dividend yield—

Beta1.09vs XLV 0.56

Year to date +51.3% · Average volume (30d) 427.4K

Analysts

Price target, next 12 months$4.00+11.1%Median of 13 analysts · vs the Aug 28 close

ConsensusHold4 of 13 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $3.60

High$4.00+11.1%

Median$4.00+11.1%

Low$4.00+11.1%

12 months agoNowIn 12 months

Latest analyst notes

No analyst notes in the last 24 months.

Earnings

EPS

Estimate−$0.23

ReportedDue Nov 4, 2026

Revenue

Estimate$31.1M

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.27	$0.09	+133.3%	$29.1M	$30.6M	+5.3%	−3.61%
May 6, 2026Q1 FY26	−$0.23	−$0.32	−39.1%	$27.7M	$27.9M	+0.8%	+4.33%
Feb 25, 2026Q4 FY25	−$0.17	−$0.19	−11.8%	$26.4M	$26.7M	+1.0%	+10.00%
Nov 5, 2025Q3 FY25	−$0.16	−$0.13	+18.8%	$26.4M	$27.1M	+2.4%	−6.61%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$29.9M	$31.2M	$27.1M	$26.8M	$27.9M	$30.6M
Gross profit	$12.3M	$13.2M	$11.8M	$11.0M	$10.5M	$13.3M
Operating income	−$18.3M	−$17.3M	−$15.7M	−$16.9M	−$23.2M	$5.4M
Net income	−$16.0M	−$19.7M	−$13.7M	−$19.3M	−$22.4M	$6.2M
Diluted EPS	−$0.21	−$0.26	−$0.19	−$0.27	−$0.32	$0.09
Gross margin	41.1%	42.1%	43.5%	41.0%	37.4%	43.5%
Operating margin	-61.0%	-55.4%	-58.0%	-63.0%	-83.0%	17.8%

Fiscal years (4-quarter sums)FY21 $233.7M · FY22 $387.5M · FY23 $405.5M · FY24 $185.8M · FY25 $115.0M

Revenue by product · Q2 FY26

Product And Services$29.7M · 97%

Other Revenues$915.0K · 3%

Revenue by geography · Q2 FY26

United States$20.2M · 66%

Africa$6.8M · 22%

Other Foreign Countries$1.9M · 6%

Europe$1.7M · 6%

Balance sheet, Jun 30, 2026Cash & short-term investments $160.6M · Total debt $12.1M · Total assets $360.6M · Shareholders' equity $317.8M

Dividends

No dividends on record.

Ownership

Institutions 80.37%55.33M sharesInsiders 6.64%4.57M sharesOther 12.99%8.95M shares

Shares outstanding 68.85M · Float 64.29M · 93.4% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	6.26M	9.09%	13F	Aug 7, 2026
Neuberger Berman Group LLC	4.69M	6.81%	13F	Aug 13, 2026
Private Management Group Inc	3.80M	5.52%	13F	Jul 31, 2026
Altai Capital Management, L.P.	3.61M	5.25%	13F	Aug 13, 2026
Vanguard Capital Management LLC	3.02M	4.38%	13F	Aug 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
May 12, 2026	Steven Kyle Boyd	director	+25,000	$2.98
May 13, 2026	Steven Kyle Boyd	director	+25,000	$3.02
May 14, 2026	Steven Kyle Boyd	director	+25,000	$2.99
Mar 20, 2026	Manner Carrie Eglinton	director, officer: President & CEO	+32,300	$2.93
Mar 20, 2026	Kenneth J. McGrath	officer: Chief Financial Officer	+32,300	$2.93